Introduction
The CD56 hematopoietic isoform of the neural cell adhesion molecule (NCAM) is a 140 kDa glycosylated molecule with an extracellular domain containing five immunoglobulin and two fibronectin type III domains. 1, 2 Its expression on peripheral blood mononuclear cells (PBMC) defines a population of natural cytotoxic cells (NCC), which includes NK and NK-T cells.
In humans, CD56 is also expressed by plasmacytoid dendritic cells (DCs), precursors and plasmacytoid DC. 3 These cells are CD4 þ IL-3Ra þ (CD123 bright ) CD11bÀ and lack myeloid markers. During analysis of cells derived from CD34 cells cultured for 2 or more weeks in interleukin-2 (IL-2) and stem cell factor (SCF), we found a monocyte population weakly expressing CD56. We hypothesized that similar cells might also occur normally in peripheral blood. Here we describe the occurrence of CD56 þ monocytes in normal individuals. These cells produced a variety of monocyte/macrophage cytokines, presented antigen, and upon LPS stimulation exhibited an antiproliferative effect on the K562 leukemia cell line.
Materials and methods

Antibodies and reagents
Fluorescein isothiocyanate (FITC)-conjugated anti-CD56, anti-CD14, anti-FcgRII (CD32), anti-FcgRIII (CD16), anti-CD33, anti-CD3, anti-CD11a, allophycocyanin (APC)-conjugated anti-CD56, anti-CD11c, anti-CD38, anti-CD69, anti-CD117, PEconjugated HLA-DR, anti-CD11b, anti-FcgRI (CD64), anti-CD117, anti-CD3, anti-CD16, anti-CD56, perCP-conjugated anti-CD4, anti-CD69, anti-CD8, anti-HLA-DR, anti-CD123 and matching isotype mouse MoAbs were purchased from BD Bioscience (San Jose, CA, USA). PE-conjugated anti-CD34 was purchased from Immunotech (Marseille, France). Magnetic bead-conjugated anti-CD56 and 'MiniMacs' magnet were purchased from Miltenyi Biotec (Auburn, CA, USA). APCconjugated anti-FAS (CD95) and PE-conjugated anti-FAS ligand (CD95L) MoAbs were purchased from Caltag (Burlingame, CA, USA).
Cell isolation, activation and expansion CD34 þ cells were positively selected from healthy stem cell donor G-CSF-mobilized peripheral blood stem cells (PBSC), counted and frozen in liquid nitrogen until use. All subjects gave written informed consent to donate stem cells for research in NIH protocols 99-H-0046 and 95-H-0049. PBMC were separated by Ficoll-hypaque density separation. Cells were cultured in RPMI 1640 supplemented with 10% FCS serum, glutamine (2 mM) gentamicin, hereafter referred to as complete medium. CD34 þ cells were cultured in complete medium, in 96-well U-bottom plates (Costar), for a minimum of 10 to a maximum of 35 days. Cells were stimulated every 5-7 days with SCF (50 ng/ml) (Peprotech, Rocky Hill, NJ, USA) and IL-2 (200 U/ml). To obtain pure CD56 þ populations, CD34-derived CD56 þ cells or peripheral blood CD56 þ cells were stained with a PE-conjugated anti-CD56 MoAb and an FITC-conjugated anti-CD33 for 30 0 on ice. CD56 þ CD33 þ and CD56 þ CD33À cells were isolated by sorting using an EPICS ALTRA Flow cytometer (Beckman Coulter, Miami, FL, USA). In some experiments, the doublets were eliminated using an exclusion gate set on FITC-CD33 vs pulse width.
Monocyte and T lymphocyte selection: Leukapheresis samples containing elutriated monocytes were obtained from the NIH Blood Bank. After Ficoll gradient separation, cells were depleted of CD56 þ cells by magnetic sorting (Miltenyi, Auburn, CA, USA). Low-density PBL (mainly monocytes) and high-density cells (mostly resting lymphocyte) were separated on a 40-30% percoll gradient. Low-and high-density cells were subjected to a second round of CD56 þ cell depletion using a magnetic bead-conjugated anti-CD56. High-density cells were further depleted of CD14 þ cells using a magnetic bead-conjugated anti-CD14. Cells were passed through a magnetic column. Vigorous mechanical pressure eluted CD56 þ cells retained in the column.
Flow-cytometric analysis
Cells were stained on ice, for 30 min, washed twice, fixed in 1% paraformaldehyde (PFA) and 1-5 Â 10 4 cells were analyzed using a four-color FACSCalibur flow cytometer (Becton Dickinson, San José, CA, USA).
Proliferation assay
The proliferation of K562 or peripheral blood T lymphocytes was measured in duplicate or triplicate by tritiated thymidine incorporation ( 3 H-TdR). Cells were pulsed with 1 mCi of 3 H-TdR per well (Amersham Biosciences, Piscataway, NJ, USA). After 18 h, 3 H-TdR was measured in a b-scintillation counter. K562 proliferation was measured after 48 h culture. CMV-induced T-cell proliferation was measured after 6-days culture.
Cytokine array
CD56 þ CD33 þ cell supernatants were assessed for cytokine content in a 42 human cytokine array system (RayBiotech Inc., Norcross, GA, USA), which detects the antibody-cytokine sandwich by chemiluminescence. Briefly, electronically sorted CD56 þ CD33 þ cells were cultured in duplicate with or without LPS (1.5 mg/ml) in 96-well U-bottom plates. Supernatants were harvested at 24, 48 and 72 h and stored frozen until use. Duplicate antibody-coated membranes were incubated in 2 ml blocking buffer for 30 min. Cryopreserved supernatants were thawed, diluted 1:1 with blocking buffer and added to the membranes. After 2 h incubation at RT and agitation, membranes were washed five times and incubated with a cocktail of biotin-conjugated antibodies. After 2 h incubation, membranes were washed five times and incubated for 30 min with HRPconjugated streptavidin. Membranes were incubated in the detection system for 5 min, wrapped in plastic wrap, placed in a Kodak cassette and exposed to a X-OMAT for varying period of time.
IL-6 and IL-1b protein measurement
Electronically or magnetically sorted CD56 þ CD33 þ were cultured in CM in 96-well U-bottom plates. Supernatants were harvested on 24, 48, and 72 h cell culture. Samples were frozen until use. IL-6 content was measured by a standard quantitative commercially available immunoassay. IL-6 kit was purchased from Biosource (Camarillo, CA, USA), while IL-1b was purchased from R&D (Minneapolis, MN, USA). The minimum detectable cytokine level using these assays was 2 pg/ml for IL-6 and 1 pg/ml for IL-1b.
Statistical analysis
T-cell stimulation index (SI) was calculated by dividing the CPM of T-cell proliferation cultured in the presence of the stimulators by the CPM of unstimulated T cells. Results of multiple T-cell stimulation experiments were expressed as means and standard error of mean (s.e.m.). The differences between CD56 þ and CD56À populations were calculated with a Mann-Whitney test or a paired t-test. CD11a þ had lymphoid morphology, expressed CD11b weakly and the killer immunoglobulin-like receptor (KIR) NKG2A/CD94, and were CD33À. 6 Notably, a population of CD56 þ CD11aÀ was observed. These cells may represent an early NK population that has not yet acquired CD11a (Figure 1 ).
CD56 low CD33 þ cells circulate in normal individuals
We next studied PBMC from 13 healthy adults and identified a minor population of CD56 low CD33 þ cells. They represented a mean of 1.371.0% (range 0.16-3.5%) of PBMC and a mean of 1179% (range 1.5-28%) of CD56 þ cells (Table 1) . They had similar FSC-H, SSC-H, and CD11b expression intensity to cultured CD56 low CD33 þ cells, suggesting that the circulating cells represented a similar maturational stage of a CD34 þ derived myeloid population (Figure 2 ). (Figure 3 ). To confirm their monocytic origin, CD56 low CD33 þ cells were incubated in the presence of MoAbs specific for monocyte cell surface antigens CD14, CD64, CD32, HLA-DR and CD16. We also evaluated the plasmacytoid DC antigen IL-3a receptor (CD123). In five individuals CD56 low CD33 þ cells comprised 71720% CD14 þ , 81.576% CD64 þ , 8971.4% CD32 þ , 9177.4% HLA-DR, 9178% CD123 þ and 12718% CD16 þ , confirming their monocytic nature. Interestingly, CD16 distribution on CD56 low CD33 þ cells identified two further CD56 low CD33 þ cell subsets. The CD16 þ cell population may represent a fraction of the previously described TNF-a producing CD16 þ small monocytes. Consistent with their NK phenotype, CD56 þ CD33À cells were 2.472.2% CD14 þ , 0.270.3% CD64 þ , 2.671.8% CD32 þ , 2.671.9% DR þ , 4.271% CD123 þ and 72.9726% CD16 þ (Figure 4 ).
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Cytokine production
Cytokines present in 24, 48 and 72 h supernatants from CD56 low CD33 þ cells were analyzed by a cytokine array. As shown in Figure 5 , CD56 low CD33 þ cells produce a variety of cytokines including IL-1b and IL-6. As IL-1b and IL-6 are essential for the generation of CTL responses and alloantigen presentation by B cells, 7, 8 we sought to confirm their production by an immunoenzymatic assay. CD56 low CD33 þ cells from two healthy blood donors were flow-sorted and cultured in complete medium for 72 h. In the absence of stimulation, both donors produced IL-6 and IL-1b. The first donor-conditioned medium contained 0.376 ng/ml of IL-1b a and 6 ng/ml of IL-6, while the second donor-conditioned medium contained 0.1 ng/ CD56 þ peripheral blood monocytes G Sconocchia et al ml of IL-1b and 2.2 ng/ml of IL-6-conditioned medium (data not shown), confirming the cytokine array data.
Functional characterization of CD56 low CD33 þ monocytes
It has been previously reported that large Fc gamma receptorpositive monocytes (FcR þ ) are weak APC, but are cytostatic to tumor cell lines and suppress PHA-and antigen-induced lymphoproliferation, while small monocytes present antigens but have weak cytostatic effects. 9 We therefore tested the functional characteristics of CD56 low CD33 þ CD14 þ cells and compared them with CD56ÀCD33 þ CD14 þ PBM. Purified T cells from three cytomegalovirus (CMV) seropositive donors were cultured in the presence of incremental doses of flowsorted monocytes primed with CMV antigen. After 5 days culture, CD56 low CD33 þ CD16À and CD14 þ CD56À monocytes produced comparable dose-dependent stimulation of proliferation. However, when allogeneic T cells of one normal donor were stimulated with selected monocytes of five HLAmismatched normal donors, the CD56 þ monocytes induced greater proliferation than the CD56À population. As shown in Figure 6 , the stimulation index (SI) of T-cell proliferation in the presence of 0. 
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Figure 5
Cytokine production by CD56 low CD33 þ PBM. CD56 low CD33 þ PBM were cultured in CM for 72 h. Supernatants were harvested as indicated in Materials and Methods. The total cytokine content was analyzed using a cytokine array. Data are representative of two subjects tested. Cytokine relative units were calculated using the optical density units of the positive control contained in the figure giving cytokine units ¼ 100. (Figure 7 ). To identify mechanisms responsible for the observed inhibitory effects, we evaluated the FAS expression on K562 cells. K562 cells expressed only low levels of FAS and soluble FAS ligand (L) induced only partial inhibition of K562 proliferation. We next assessed the effect of antiproliferative cytokines TGFb and TNFa on K562 cell proliferation. None of these cytokines affected K562 proliferation, indicating that these molecules were not involved in the proliferation inhibition of K562 (data not shown).
Discussion
We found that stimulation of G-CSF-mobilized CD34 þ cells with IL-2 and SCF generated CD56 þ cells, which segregated into a CD56 high subset with phenotypic and morphologic features of NK cells and a CD56 low subset with phenotypic and morphologic features of monocytes. This prompted us to search for these unusual monocytes in peripheral blood. Analysis of PBMC from 13 normal donors confirmed that low frequencies of CD56 low CD33 þ cells indeed circulate in healthy individuals. While there is no direct evidence that the circulating cells represent the same stage of development as those identified in culture, their phenotypic similarity suggests that they are a terminally differentiated CD34-derived cell subset. Phenotypic, morphologic and functional analysis of blood CD56 low CD33 þ cells further defined them as a mature monocyte subset. To the best of our knowledge, this is the first description of a CD56 low monocyte subset. In previous studies, CD56 has been used to characterize PBMC populations phenotypically and functionally. Lanier et al and Phillips et al demonstrated that a combination of NK-and Tcell markers with CD56 defined three subsets of cells with distinct lymphokine-activated killer (LAK) activity. [10] [11] [12] CD56 has also been used as a diagnostic and prognostic marker for myeloid malignancies. 13, 14 More recently, CD56 in combination with DC markers has facilitated the identification of a subset of plasmacytoid DCs (DC2). 15 Here we show that CD56 used with myeloid markers permits the characterization of a myeloid CD56 cell subpopulation. While CD56 is known to play a morphogulatory role during the early development of the embryo, 1 little is known about its hematopoietic functions other than its association with cells exhibiting natural immunity. It has been proposed that CD56 þ cells cooperate with LFA-1 and -3 to enhance interactions between NK and other CD56 þ cells, leading to increased cytotoxicity. 16 However, several investigators have failed to demonstrate direct involvement of CD56 in NK cell-mediated cytotoxicity. 17, 18 Interestingly, CD56 shows homophilic interaction. 2 After stimulation with IL-2, CD56 is promptly upregulated (Sconocchia, unpublished observation) . This may in turn induce changes in the avidity of CD56 homophilic binding. As a consequence, we speculate that CD56 þ monocytes, NK, NK-T and plasmacytoid DC can interact and mutually upregulate CD56 through CD56 homophilic binding.
The occurrence of a rare CD33 þ CD56 þ acute leukemia is further evidence supporting the existence in vivo of a CD56 þ monocyte population. This aggressive acute leukemia, sometimes termed a hybrid/natural killer leukemia, has a monocytic appearance with scant cytoplasm containing azurophilic granules, and finely granular sudan black B and/or myloperoxidase activity. 19 Since CD123 antigen is not only expressed on plasmacytoid DCs but is also present at low levels on a fraction of normal monocyte, we may consider CD56 low CD33 þ monocyte the nonleukemic counterpart of an essentially myeloid-derived leukemia. Alternatively, considering that CD56 is also expressed on a subset of plasmacytoid DCs and their precursors, 15 CD56 low CD33 þ cell type may be the normal counterpart of the rare CD56 þ CD4 þ CD123 þ CD11bÀCD33 þ plasmacytoid leukemia (DC2) that, until recently, was considered to be of NK origin. 15, 20, 21 However, the possibility is therefore raised that peripheral blood CD56 low CD33 þ cells are monocytic precursors of CD56 þ DC2 cells. Another possibility is that CD56 low CD33 þ cells could be part of the population of previously described peripheral blood monocytes bearing the NK antigen, CD16. [22] [23] [24] Human CD16 þ monocytes represent 10% of the total peripheral blood monocytes. They promptly expand in HIV infection and during sepsis. 25, 26 Consistent with their ability of being major producers of TNFa 27 and minimal producers of IL-10, 28 they are powerful proinflammatory cells. They are CD64 weakly positive and CD11b low . 29 While the major population of CD56 low CD33 þ were CD16À, a minor population were CD16 þ and may therefore fall into the category of CD16 þ monocytes. However, since they secreted IL-10 and were CD11b high , they more likely represent a 'non-NK-like' population CD56 þ peripheral blood monocytes G Sconocchia et al of peripheral blood monocytes. We need also to consider that a fraction of CD56 low CD33 þ CD123 þ cells had a high size scatter; thus, it is also possible that some of these cells may be basophils.
We also found substantial functional differences between CD56 low and regular CD14 þ peripheral blood monocytes. Monocytes can exert both cytotoxic and cytostatic effects on tumor cells [30] [31] [32] [33] [34] [35] [36] and have APC functions. In particular, large FcR þ monocytes are weak APC, but are considered to have mainly regulatory functions with unique antiproliferative effects on tumor and normal cells. In contrast, small monocytes are FcR low and exhibited strong APC function with low antiproliferative activity. 37 Our experiments suggested that CD56 low monocytes have superior APC function with low (but LPSenhanced) antiproliferative effects on the K562 cell line. We were unable to determine why CD56 þ and CD56À PBM differ in their ability to inhibit K562 proliferation. The effect was not due to different levels of FAS/L expression by the effectors nor to differences in their production of cytostatic cytokines TNFa 38 and TGF-b. 39 A further possibility is that the weak antiproliferative effect of CD56 þ monocytes relates to reduced production of oxygen or nitrogen radicals compared with the CD56À monocyte. 40 Finally, we can only speculate about the functional role of this monocyte subset. It is possible that they have a regulatory function, limiting the cytotoxic and cytostatic actions of inflammatory cells by IL-10 production. Detailed studies of their interactions with lymphocytes and NK cells are needed to better define their role in the immune response.
